Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Evaluation of electrochemiluminescence immunoassays for immunosuppressive drugs on the Roche cobas e411 analyzer.

Fung AWS, Knauer MJ, Blasutig IM, Colantonio DA, Kulasingam V.

Version 2. F1000Res. 2017 Oct 13 [revised 2017 Jan 1];6:1832. doi: 10.12688/f1000research.12775.2. eCollection 2017.

2.

Candidate recommendations for protein electrophoresis reporting from the Canadian Society of Clinical Chemists Monoclonal Gammopathy Working Group.

Booth RA, McCudden CR, Balion CM, Blasutig IM, Bouhtiauy I, Rodriguez-Capote K, Catomeris P, Chan PC, Chen Y, Collier C, Hauff K, Kalra J, Li D, Lin DC, Lou AH, Meng QH, Morrison T, Pasic MD, Qureshi M, Randell E, Sohn KY, Thakur V, Thomas D, Thoni A, Tomalty C, Yang L, Zamkanei M.

Clin Biochem. 2018 Jan;51:10-20. doi: 10.1016/j.clinbiochem.2017.10.013. Epub 2017 Oct 20.

3.

Generation of monoclonal antibodies and development of an immunofluorometric assay for the detection of CUZD1 in tissues and biological fluids.

Farkona S, Soosaipillai A, Filippou P, Korbakis D, Serra S, Rückert F, Diamandis EP, Blasutig IM.

Clin Biochem. 2017 Dec;50(18):1168-1174. doi: 10.1016/j.clinbiochem.2017.07.012. Epub 2017 Jul 23.

PMID:
28746862
4.

A patient with monoclonal gammopathy-related nephrotic syndrome revealed no electrophoretic "nephrotic pattern" or skewed free light chain ratio.

Truong D, Blasutig IM, Kulasingam V, Chan PC.

Clin Biochem. 2018 Jan;51:110-111. doi: 10.1016/j.clinbiochem.2017.06.012. Epub 2017 Jul 1. No abstract available.

PMID:
28676334
5.

The Phoenix Rises: The Rebirth of Cancer Immunotherapy.

Blasutig IM, Farkona S, Buchbinder EI, Luke JJ, Sharma P, Sznol M.

Clin Chem. 2017 Jul;63(7):1190-1195. doi: 10.1373/clinchem.2016.267849. Epub 2017 May 17. No abstract available.

6.

Evaluation of the N-latex serum free light chain assay on the Siemens BNII analyzer and agreement with The Binding Site FreeLite assay on the SPAPlus.

White-Al Habeeb NMA, Earle T, Spencer M, Blasutig IM.

Clin Biochem. 2018 Jan;51:90-96. doi: 10.1016/j.clinbiochem.2017.05.009. Epub 2017 May 13.

PMID:
28512013
7.

Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases.

Farkona S, Soosaipillai A, Filippou P, Liaskos C, Bogdanos DP, Diamandis EP, Blasutig IM.

Clin Chem Lab Med. 2017 Aug 28;55(10):1574-1581. doi: 10.1515/cclm-2016-1120.

PMID:
28343172
8.

Cancer immunotherapy: the beginning of the end of cancer?

Farkona S, Diamandis EP, Blasutig IM.

BMC Med. 2016 May 5;14:73. doi: 10.1186/s12916-016-0623-5. Review.

9.

Analytical evaluation of the BioPlex® 2200 25-OH vitamin D total assay.

Abou El Hassan M, Lin DCC, Earle T, Spencer M, Blasutig IM.

Clin Biochem. 2016 Jun;49(9):723-725. doi: 10.1016/j.clinbiochem.2016.03.010. Epub 2016 Apr 23.

PMID:
27112381
10.

Miniaturization: The future of laboratory medicine.

Blasutig IM.

Clin Biochem. 2016 Jan;49(1-2):2-3. doi: 10.1016/j.clinbiochem.2015.11.007. Epub 2015 Nov 18. No abstract available.

PMID:
26601571
11.

Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer.

Chan A, Prassas I, Dimitromanolakis A, Brand RE, Serra S, Diamandis EP, Blasutig IM.

Clin Cancer Res. 2014 Nov 15;20(22):5787-95. doi: 10.1158/1078-0432.CCR-14-0289. Epub 2014 Sep 19.

12.

False biomarker discovery due to reactivity of a commercial ELISA for CUZD1 with cancer antigen CA125.

Prassas I, Brinc D, Farkona S, Leung F, Dimitromanolakis A, Chrystoja CC, Brand R, Kulasingam V, Blasutig IM, Diamandis EP.

Clin Chem. 2014 Feb;60(2):381-8. doi: 10.1373/clinchem.2013.215236. Epub 2013 Oct 4.

13.

Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.

Makawita S, Dimitromanolakis A, Soosaipillai A, Soleas I, Chan A, Gallinger S, Haun RS, Blasutig IM, Diamandis EP.

BMC Cancer. 2013 Sep 3;13:404. doi: 10.1186/1471-2407-13-404.

14.

Laminin, gamma 2 (LAMC2): a promising new putative pancreatic cancer biomarker identified by proteomic analysis of pancreatic adenocarcinoma tissues.

Kosanam H, Prassas I, Chrystoja CC, Soleas I, Chan A, Dimitromanolakis A, Blasutig IM, Rückert F, Gruetzmann R, Pilarsky C, Maekawa M, Brand R, Diamandis EP.

Mol Cell Proteomics. 2013 Oct;12(10):2820-32. doi: 10.1074/mcp.M112.023507. Epub 2013 Jun 24.

15.

Comparison of three anti-dsDNA assays: performance and correlation with systemic lupus erythematosus disease activity.

Venner AA, Ibañez D, Gladman DD, Urowitz MB, MacKinnon A, Blasutig IM, Yip PM.

Clin Biochem. 2013 Mar;46(4-5):317-20. doi: 10.1016/j.clinbiochem.2012.12.004. Epub 2012 Dec 12.

PMID:
23246539
16.

Strategies for discovering novel pancreatic cancer biomarkers.

Chan A, Diamandis EP, Blasutig IM.

J Proteomics. 2013 Apr 9;81:126-34. doi: 10.1016/j.jprot.2012.09.025. Epub 2012 Sep 28. Review.

17.

The long journey of cancer biomarkers from the bench to the clinic.

Pavlou MP, Diamandis EP, Blasutig IM.

Clin Chem. 2013 Jan;59(1):147-57. doi: 10.1373/clinchem.2012.184614. Epub 2012 Sep 27. Review.

18.

Analytical evaluation of the VITROS 5600 Integrated System in a pediatric setting and determination of pediatric reference intervals.

Blasutig IM, Jung B, Kulasingam V, Baradaran S, Chen Y, Chan MK, Colantonio D, Adeli K.

Clin Biochem. 2010 Sep;43(13-14):1039-44. doi: 10.1016/j.clinbiochem.2010.05.011. Epub 2010 May 23.

PMID:
20501331
19.

Pediatric reference intervals for 28 chemistries and immunoassays on the Roche cobas 6000 analyzer--a CALIPER pilot study.

Kulasingam V, Jung BP, Blasutig IM, Baradaran S, Chan MK, Aytekin M, Colantonio DA, Adeli K.

Clin Biochem. 2010 Sep;43(13-14):1045-50. doi: 10.1016/j.clinbiochem.2010.05.008. Epub 2010 May 23.

PMID:
20501329
20.

Nck proteins maintain the adult glomerular filtration barrier.

Jones N, New LA, Fortino MA, Eremina V, Ruston J, Blasutig IM, Aoudjit L, Zou Y, Liu X, Yu GL, Takano T, Quaggin SE, Pawson T.

J Am Soc Nephrol. 2009 Jul;20(7):1533-43. doi: 10.1681/ASN.2009010056. Epub 2009 May 14.

21.

Phosphorylated YDXV motifs and Nck SH2/SH3 adaptors act cooperatively to induce actin reorganization.

Blasutig IM, New LA, Thanabalasuriar A, Dayarathna TK, Goudreault M, Quaggin SE, Li SS, Gruenheid S, Jones N, Pawson T.

Mol Cell Biol. 2008 Mar;28(6):2035-46. doi: 10.1128/MCB.01770-07. Epub 2008 Jan 22.

22.

Non-canonical interaction of phosphoinositides with pleckstrin homology domains of Tiam1 and ArhGAP9.

Ceccarelli DF, Blasutig IM, Goudreault M, Li Z, Ruston J, Pawson T, Sicheri F.

J Biol Chem. 2007 May 4;282(18):13864-74. Epub 2007 Mar 5.

23.

Determination of the Plk4/Sak consensus phosphorylation motif using peptide spots arrays.

Leung GC, Ho CS, Blasutig IM, Murphy JM, Sicheri F.

FEBS Lett. 2007 Jan 9;581(1):77-83. Epub 2006 Dec 11.

24.

Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes.

Jones N, Blasutig IM, Eremina V, Ruston JM, Bladt F, Li H, Huang H, Larose L, Li SS, Takano T, Quaggin SE, Pawson T.

Nature. 2006 Apr 6;440(7085):818-23. Epub 2006 Mar 8.

PMID:
16525419

Supplemental Content

Loading ...
Support Center